Table 2.
Relation of MMP12 Expression With Progression-free Interval (PFI) and Disease-free Interval (DFI) of Cancer Patients.
| Cancer (sample) | PFI HR a | P-value | Cancer (sample) | DFI HR | P-value |
|---|---|---|---|---|---|
| ACC (40) | 1.008 | .965 | ACC (20) | 165.846 | .223 |
| BLCA (415) | 1.003 | .928 | BLCA (189) | .999 | .995 |
| BRCA (1142) | .973 | .632 | BRCA (975) | .988 | .873 |
| CESC (276) | .960 | .507 | CESC (173) | .858 | .147 |
| CHOL (40) | .884 | .450 | CHOL (29) | 1.019 | .910 |
| COAD (314) | .934 | .247 | COAD (121) | .684 | .020 |
| DLBC (43) | .930 | .697 | DLBC (26) | .366 | .119 |
| ESCA (185) | 1.189 | .002 | ESCA (91) | 1.219 | .055 |
| GBM (113) | .991 | .947 | HNSCC (134) | 1.202 | .072 |
| HNSCC (553) | .993 | .839 | KICH (36) | .027 | .538 |
| KICH (77) | 2.011 | .089 | KIRC (112) | .764 | .582 |
| KIRC (489) | 1.202 | .009 | KIRP (133) | 1.279 | .463 |
| KIRP (237) | 1.048 | .810 | LGG (52) | 1.083 | .894 |
| LGG (204) | .660 | .207 | LIHC (274) | 1.056 | .532 |
| LIHC (326) | 1.061 | .328 | LUAD (331) | 1.160 | .003 |
| LUAD (545) | 1.037 | .259 | LUSC (316) | .950 | .423 |
| LUSC (515) | .981 | .638 | MESO (11) | 1.987 | .085 |
| MESO (65) | .966 | .783 | OV (191) | .967 | .632 |
| OV (382) | .916 | .087 | PAAD (71) | 1.382 | .001 |
| PAAD (175) | 1.127 | .047 | PCPG (77) | 2.092 | .469 |
| PCPG (92) | 1.444 | .084 | PRAD (367) | .534 | .125 |
| PRAD (518) | 1.155 | .330 | READ (32) | 1.185 | .620 |
| READ (100) | .962 | .760 | SARC (129) | 1.223 | .002 |
| SARC (216) | 1.160 | .003 | STAD (252) | .864 | .033 |
| SKCM (93) | 1.125 | .455 | TGCT (101) | 1.004 | .967 |
| STAD (409) | .903 | .009 | THCA (357) | 1.409 | .110 |
| TGCT (125) | .992 | .923 | UCEC (126) | .729 | .077 |
| THCA (502) | 1.086 | .575 | UCS (26) | .894 | .766 |
| THYM (106) | 2.175 | .029 | |||
| UCEC (178) | .899 | .313 | |||
| UCS (54) | 1.211 | .103 | |||
| UVM (32) | 1.186 | .389 |
aNotes: hazard ratio.